|Bid||10,402.00 x 0|
|Ask||10,404.00 x 0|
|Day's range||10,386.00 - 10,458.00|
|52-week range||6,499.80 - 11,000.00|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||129.54|
|Earnings date||28 Apr 2022 - 02 May 2022|
|Forward dividend & yield||2.10 (2.04%)|
|Ex-dividend date||24 Feb 2022|
|1y target est||110.79|
While the world wrestles with the impact of Covid, inflation and geopolitical strife, investors are naturally wondering what lies in store for some of the coun...
WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2
Does the May share price for AstraZeneca PLC ( LON:AZN ) reflect what it's really worth? Today, we will estimate the...